Validation of claims‐based algorithms for identification of high‐grade cervical dysplasia and cervical cancer

High‐grade cervical dysplasia or cervical intraepithelial neoplasia grade 2 or worse has been widely used as a surrogate endpoint in cervical cancer screening or prevention trials.

[1]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[2]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[3]  R. Platt,et al.  Outpatient urticaria diagnosis codes have limited predictive value for same-day influenza vaccine adverse event detection. , 2010, Journal of clinical epidemiology.

[4]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[5]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[6]  D. Wilbur,et al.  Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. , 2009, Archives of pathology & laboratory medicine.

[7]  M F Mitchell,et al.  Cervical human papillomavirus infection and intraepithelial neoplasia: a review. , 1996, Journal of the National Cancer Institute. Monographs.

[8]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[9]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[10]  C. Wheeler,et al.  Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.

[11]  Edson Duarte Moreira Júnior,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.

[12]  Diane Solomon,et al.  2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. , 2007, American journal of obstetrics and gynecology.

[13]  M. Gail,et al.  The promise and peril of surrogate end points in cancer research , 2002, Nature Reviews Cancer.

[14]  Li Zhi-gang,et al.  2006 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests , 2008 .